Format

Send to

Choose Destination
See comment in PubMed Commons below
J Neurovirol. 2006 Aug;12(4):328-31.

A placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathy.

Author information

1
University of Rochester, Rochester, New York 14620, USA. Giovanni.schifitto@ctcc.rochester.edu

Abstract

Distal sensory polyneuropathy (DSP) is the most frequent neurological complication of HIV infection. Neuropathic symptoms vary from mild paresthesias to severe pain that respond only partially to symptomatic treatment. Forty-five subjects with human immunodeficiency virus (HIV)-associated symptomatic DSP (SDSP) were enrolled in a randomized, multicenter, 16-week placebo-controlled study of memantine, an N-methyl-D-aspartate (NMDA) uncompetitive antagonist. Although memantine was well tolerated, no trend toward clinical benefit was observed. Results were similar to those of other pilot studies of memantine for neuropathic pain unrelated to HIV, suggesting that memantine is ineffective for the symptomatic treatment of HIV-associated SDSP.

PMID:
16966223
DOI:
10.1080/13550280600873835
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center